目的 探究复方麝香注射液联合注射用尤瑞克林治疗急性脑梗死的临床疗效。方法 选取2016年3月—2017年12月于上海市第八人民医院收治的急性脑梗死患者150例作为研究对象，按随机数字表法将患者分为对照组和治疗组，每组各75例。对照组患者静脉滴注注射用尤瑞克林，0.15 PNA加入到0.9%氯化钠注射液100 mL中，30 min滴注完毕，1次/d。治疗组在对照组治疗的基础上静脉滴注复方麝香注射液，20 mL加入到0.9%氯化钠注射液250 mL中，1次/d。两组患者均连续治疗14 d。观察两组患者的临床疗效，比较治疗前后两组的美国国立卫生研究院卒中量表评分（NIHSS）、ADL评分、血液流变学指标和炎性因子水平。结果 治疗后，对照组和治疗组的总有效率分别为80.00%、92.00%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组NIHSS评分明显下降，ADL评分明显上升，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后治疗组NIHSS评分显著低于对照组，ADL评分显著高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血浆黏度（PV）、全血高切黏度（HBV）、全血低切黏度（LBV）和红细胞压积（HCT）水平均明显下降，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后治疗组血液流变学指标均显著低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清肿瘤坏死因子（TNF-α）、白细胞介素-6（IL-6）和金属基质蛋白酶（MMP-9）水平均明显下降，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后治疗组炎性因子水平显著低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 复方麝香注射液联合注射用尤瑞克林治疗急性脑梗死疗效显著，可促进患者神经功能的恢复，改善血流动力学指标及炎症反应，具有一定的临床推广应用价值。

Objective To explore the clinical efficacy of Compound Shexiang Injection combined with Urinary Kallidinogenase for injection in treatment of acute cerebral infarction. Methods Patients (150 cases) with acute cerebral infarction in the Eighth People's Hospital of Shanghai from March 2016 to December 2017 were randomly divided into control group and treatment group, and each group had 75 cases. Patients in the control group were iv administered with Urinary Kallidinogenase for injection, 0.15 PNA added into 0.9% sodium chloride injection 100 mL, infusion was completed within 30 min, once daily. Patients in the treatment group were iv administered with Compound Shexiang Injection, 20 mL added into 0.9% sodium chloride injection 250 mL, once daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the NIHSS scores, ADL scores, hemorheological indexes, and inflammatory factor levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 80.00% and 92.00%, respectively, and there were differences between two groups (P<0.05). After treatment, the NIHSS scores were significantly decreased in two groups, but the ADL scores were significantly increased, and there were differences in the same group (P<0.05). After treatment, the NIHSS score in the treatment group were lower than those in the control group, but the ADL score were higher than those in the control group, and there were differences between two groups (P<0.05). After treatment, the levels of SV, HBV, LBV, and HCT in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the hemorheological indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of TNF-α, IL-6, and MMP-9 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the inflammatory factor levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Compound Shexiang Injection combined with Urinary Kallidinogenase for injection has obvious curative effect in treatment of acute cerebral infarction, can promote the recovery of neurological function, improve hemodynamic indexes and inflammatory response, which has a certain clinical application value.